
Wholesale pricing available for approved accounts
Modified Growth Hormone Releasing Factor (Mod GRF 1-29) — a 30 amino acid peptide analog of GHRH without Drug Affinity Complex. Utilized in endocrine and growth hormone axis research.
All Signal peptides undergo rigorous third-party testing and are guaranteed ≥99% purity. Every batch comes with a Certificate of Analysis (COA) verified through AuthentiChain's blockchain verification system.
Orders placed before 12PM EST ship same-day via cold chain logistics. Products are shipped in insulated packaging with dry ice to maintain temperature integrity. Standard delivery is 1–3 business days.
Approved accounts have access to flexible payment terms including NET 30, wire transfer, and credit card. Volume-based pricing is automatically applied at checkout based on your order quantity.
Absolutely. Contact your dedicated account manager or reach out to info@signalpeps.com with the product name and lot number. COAs are also available digitally through our AuthentiChain verification badge on each product page.
In-depth findings from peer-reviewed preclinical and clinical studies
CJC-1295 (Modified GRF 1-29) is a synthetic analog of growth hormone-releasing hormone with enhanced stability against enzymatic degradation, designed to stimulate sustained, pulsatile GH release.
In healthy adults, CJC-1295 increased mean plasma GH concentrations 2- to 10-fold for 6+ days and IGF-1 levels 1.5- to 3-fold for 9–11 days after a single injection. With multiple doses, IGF-1 remained elevated for up to 28 days.
Journal of Clinical Endocrinology & Metabolism (2006)Strategic amino acid substitutions in CJC-1295 provide resistance to degradation by DPP-4 enzymes, which rapidly break down native GHRH — resulting in significantly prolonged biological activity compared to endogenous GHRH.
Journal of Clinical Endocrinology & Metabolism (2006)CJC-1295 binds GHRH receptors in the pituitary gland, stimulating endogenous GH release while preserving normal pulsatile secretion patterns. Research suggests downstream effects on lean mass, protein synthesis, and adipose tissue metabolism.
Journal of Clinical Endocrinology & Metabolism (2006)When combined with GHS receptor agonists like Ipamorelin, CJC-1295 demonstrated synergistic GH release — the combination targets complementary pathways (GHRH receptor + ghrelin receptor) for more robust and sustained elevation.
Journal of Clinical Endocrinology & Metabolism (2005)All findings above are sourced from peer-reviewed journals for educational reference. This product is for research purposes only — not for human consumption. Preclinical results may not translate to human outcomes.
Three simple steps to access premium research peptides
Submit a quick application with your business details. Takes less than 2 minutes.
Our team reviews applications within 1–2 business days. You'll receive an email once approved.
Browse the catalog, select quantities, and checkout. Volume pricing applies automatically.
All products are for research and laboratory purposes only. Not intended for human or animal consumption. Only qualified professionals should handle these products.